Hyeyeong Kim

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 415 citations · Full text

Surgical Oncology, Hepatology, Medicine +8

Use of macrophages to deliver therapeutic and imaging contrast agents to tumors

Jinhyang Choi, Hyeyeong Kim, Eun Jin Ju et al. · Biomaterials · 2012 · 212 citations

Contrast Agents, Oncologic Imaging, Imaging Agent +10

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma

Hannah Yang, Beodeul Kang, Yeonjung Ha et al. · JHEP Reports · 2023 · 73 citations · Full text

Reduced Clinical Benefit, Hepatology, Unresectable Hepatocellular Carcinoma +8

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

Beom Kyung Kim, Jaekyung Cheon, Hyeyeong Kim et al. · Cancers · 2022 · 64 citations · Full text

First-line Therapy, Pathology, Pharmacotherapy +18

Association of High Levels of Antidrug Antibodies Against Atezolizumab With Clinical Outcomes and T-Cell Responses in Patients With Hepatocellular Carcinoma

Chan Kim, Hannah Yang, Il Hwan Kim et al. · JAMA Oncology · 2022 · 53 citations · Full text